Online inquiry

IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12131MR)

This product GTTS-WQ12131MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD248 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_020404.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57124
UniProt ID Q9HCU0
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12131MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3695MR IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BAY 2287409
GTTS-WQ14561MR IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA aCD1919
GTTS-WQ8961MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ14260MR IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA RG-7116
GTTS-WQ6547MR IVTScrip™ mRNA-Anti-TNF, D2E7(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA D2E7
GTTS-WQ11921MR IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MLN2045
GTTS-WQ2115MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
GTTS-WQ702MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA A-1230717
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW